Exelixis | SCHULD



Debt Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2024-12
Agios Pharmaceuticals USD 0 0 2024-12
Amgen USD 60.1B 299M 2024-12
AstraZeneca USD 30.3B 1.27B 2024-12
Bayer EUR 40.7B 465M 2024-12
BioMarin Pharmaceutical USD 596.24M 1.61M 2024-12
Bristol-Myers Squibb USD 49.65B 103M 2024-12
Cytokinetics USD 657.12M 1.1M 2024-12
Eisai JPY 219.1B 36.2B 2024-12
Eli Lilly USD 33.64B 2.52B 2024-12
Exelixis USD 0 0 2025-01
Genmab DKK 1.03B 42M 2024-12
Glaxosmithkline GBP 16.99B 927M 2024-12
Incyte USD 37.96M 5.81M 2024-12
Ionis Pharmaceuticals USD 1.25B 32.8M 2024-12
MacroGenics USD 0 0 2024-12
Merck USD 37.11B 1.02B 2024-12
Moderna USD 62M 593M 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 31.26B 828M 2024-12
Pfizer USD 64.35B 3.35B 2024-12
Sanofi 17.91B 5.85B 2024-12
Takeda JPY 4.84T 211.04B 2024-12
Ultragenyx Pharmaceutical USD 0 0 2024-12
Xencor USD 163.61M 145.69M 2024-12



Exelixis SCHULD - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Apr 2025.